Study S000539

Investigation of the Safety and Efficacy of Semaglutide s.c. in Combination With NNC0480-0389 in Participants With Type 2 Diabetes - a Dose Finding Study

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05144984
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 500
Start: 2021-11-29
Primary completion: 2023-02-13
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:NNC0480-0389; DRUG:Semaglutide; DRUG:Placebo (NNC080-0389); DRUG:Placebo (semaglutide)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1259-2741; EUDRACT_NUMBER:2020-004863-14; OTHER:jRCT2031210474

Registered primary outcomes

Change From Baseline in Glycosylated Haemoglobin (HbA1c) [Baseline (week 0), (week 34)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.